Unichem Laboratories Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Revenue from operations jumped 43.6% year on year (YoY) to Rs 434.38 crore in the quarter ended 31 March 2023.

The durg maker recored profit before exceptional item and tax of Rs 15.95 crore in Q3 FY24 as compared with loss before exceptional item and tax of Rs 61.28 crore in Q3 FY23.

The firm reported an expectional gain of Rs 68.01 crore on account of disposal of investment and property, plant and equipment.

Total expense increased 13.04% to Rs 429.70 crore in Q3 FY24 over Q3 FY23. Cost of materials consumed was at Rs 193.92 crore (up 51.92% YoY) while employee cost stood at Rs 98.11 crore (up 8.33% YoY).

On nine-months basis, the firm posted consolidated net profit of Rs 58.83 crore in 9M FY24 as against net loss of Rs 157.96 crore in 9M FY23. Net sales rose 35.31% YoY to Rs 1,273.19 crore in 9M FY24.

Unichem Laboratories is a pharmaceutical company. It addresses the needs of therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.

The counter hit a record high at Rs 559.30 in today’s intraday session.

Powered by Capital Market - Live News

Net profit of Unichem Laboratories reported to Rs 83.99 crore in the quarter ended December 2023 as against net loss of Rs 63.93 crore during the previous quarter ended December 2022. Sales rose 43.60% to Rs 434.38 crore in the quarter ended December 2023 as against Rs 302.50 crore during the previous quarter ended December 2022.

Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2024.

Powered by Capital Market - Live News

The approved abbreviated new drug application (ANDA) is a generic version of Cardura tablets from Viatris Specialty, LLC.

Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem’s Goa Plant.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

The pharmaceutical company’s consolidated net loss reduced to Rs 24.49 crore in Q2 FY24 as against net loss of Rs 70.67 crore recorded in Q2 FY23. Revenue from operations rose 26.4% YoY to Rs 415.63 crore in Q2 FY24.

The counter hit a life-time high at Rs 479.25 in today’s intraday session.

Powered by Capital Market - Live News